ArticleClinicoEconomics and outcomes research : CEOR2017

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer.

Dolores Isla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.